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Background. The aim of this study was to show the importance of the bone marker procollagen type 1 aminoterminal propeptide
(P1NP) in detecting bone metastases in women suﬀering from breast cancer. We furthermore investigated to what degree P1NP is
correlated to the degree of bone metastases, and if P1NP is increased in patients with metastases other than bone. Patients and
Methods. We analyzed 80 serum samples of women (17 premenopausal/63 postmenopausal) with breast cancer. Therefore we used
a speciﬁc immunoassay “ELECSYS 2010” by Roche Diagnostics. We divided our group of patients with regard to menopausal sta-
tus, sites of metastases and number of bone metastases. Results. As a result we found higher concentrations of P1NP in women
with radiologically conﬁrmed bone metastases (median: 125.75ng/mL) in comparison to the collective without bone involvement
(median: 73.61ng/mL). However, both groups showed values above the applied cutoﬀ values of median 27.8ng/mL for premeno-
pausal women and median: 37.1ng/mL for the postmenopausal group due to the fact that all patients had cancer. Furthermore
higher P1NP concentrations were found in women with more than 5 sites of bone metastases (median: 183.9ng/mL) than in pa-
tientswithonlyonesiteofbonemetastases(median:37ng/mL).Alsopatientswithnoboneinvolvementbutothersitesofmetasta-
ses showed quite high P1NP concentrations (median: 73.61ng/mL). Conclusion. The marker of bone turnover procollagen type 1
aminoterminalpropeptidecan beconsideredas ausefultoolfor estimatingtheextent of boneinvolvement andfor thedetection of
bonemetastases.P1NPcannotreplaceconventionalmethodsfordetectingbonemetastasessuchasradiologicalmethodsbutitcan




lar elements such as osteoclasts, osteoblasts, and osteocytes,
and there is the cellular matrix representing the main com-
ponent of bone. 90% of the cellular matrix of bone is colla-
gen tissue; the remaining 10% are noncollagenous proteins
and minerals. Especially collagen type 1 is crucial for the
typical structure of bone. Synthesis of mature type 1 collagen
is realised by the precursor proteins procollagen and tropo-
collagen. Mature type 1 collagen is a heterotrimer consisting
of two identical a1 chains and one a2 chain. During col-
lagen synthesis speciﬁc proteases remove N- and C-terminal
extensions oftheprecursor protein procollagentype1. These
extensions are referred to as the C- and N-terminal propep-
tides of procollagen type 1: P1CP and P1NP [1–3].
Bone underlies an ongoing process of reconstruction.
The two competing process are bone resorption realised by
osteoclasts and matrix formation induced by osteoblasts [1].
For the function of bone it is crucial that these processes are
balanced. However, there are diseases interfering with these
processes,suchasosteoporosisorbonemetastases.Therefore
certain markers of bone turnover have been detected and in-
vestigated in order to facilitate the assessment of bone meta-
bolism. Bone markers representing osteoblast activity and2 Pathology Research International
therefore bone formation, for instance, are alkaline phos-
phatase and its bone-speciﬁc isoenzyme, osteocalcin, procol-
lagen type 1 carboxyterminal propeptide (P1CP), and pro-
collagen type 1 aminoterminal propeptide (P1NP). Bone
markers associated with bone resorption are hydroxyprolin,
pyridinium crosslinks, c-telopeptide crosslink of type 1 col-
lagen (CTX), and n-telopeptide crosslink of type 1 collagen
(NTX).
The aim of our study was to evaluate the clinical use-
fulness of the bone formation marker procollagen type 1
aminoterminal propeptide (P1NP) in detecting bone metas-
tases in women with histologically conﬁrmed breast cancer
and to show to what extent P1NP concentrations correlate
with the degree of bone involvement.
2. Patientsand Methods
In our study we analysed serum samples of eighty women
with histologically conﬁrmed breast cancer. All women were
treated in the hospital of the Johann Wolfgang Goethe Uni-
versity in Frankfurt. The samples were collected during the
years 2005 to 2007. The women were separated into several
groupswithregardtotheirmenopausalstatus,sitesofmetas-
tases, extent of bone involvement, and hormonal therapy.
When serum samples were collected, 17 women were pre-
menopausal, 63 postmenopausal. 62 patients had radiologi-
cally conﬁrmed bone metastases (14 premenopausal, 48
postmenopausal).Inthegroupofpatientswithboneinvolve-
ment, 52 additionally had metastases in other sites. From all
patients, 15 showed no bone involvement at the date of the
study. Some of the patients received hormonal treatment but
the study did not focus on the treatment because diﬀerent
treatments develop diﬀerent P1NP values. Also the stage of
therapy inﬂuences the P1NP concentration.
For the measurement of P1NP serum concentrations
we applied the Electrochemiluminescence Immunoassay
“ECLIA”/Elecsys 1010 by ROCHE Diagnostics, Mannheim,
Germany. This assay is based on a sandwich principle using
streptavidin-coated microparticles, biotinylated monoclonal
antibodies, and monoclonal anti-P1NP antibodies associat-
ed with a ruthenium complex. For the analyses of our
data we referred to the cutoﬀ values recommended by the
median 27.8ng/mL for premenopausal women and median:
37.1ng/mL for the postmenopausal group.
AllstatisticalcalculationswereperformedwithMicrosoft
Oﬃce Excel 2003 as well as BIAS for Windows.
3. Results
In our study P1NP values ranged from 13.99ng/mL to
981.6ng/mL. In terms of our question we found signiﬁcantly
higher P1NP values in patients with proven bone involve-
ment (median: 125.75ng/mL) compared to the control
group without bone metastases (median: 73.61ng/mL). Tak-
ing into consideration the menopausal status we found for
the group of premenopausal women with bone metastases
a median P1NP value of 253.65ng/mL, and for the women
without bone involvement the median was 76.07ng/mL.
With respect to the postmenopausal women with skeletal
Table 1: P1NP in women with breast cancer without (NMS) and
with skeletal metastases (MS).
NMS MS
Number of patients 18 62
Median P1NP 73.61ng/mL 125.75ng/mL
Minimum P1NP 13.99ng/mL 14.7ng/mL




































Figure 1: ROC analyses for P1NP.
metastases the median P1NP value was 105.6ng/mL, and
withoutsuchmetastasesitwas66.71ng/mL.Theseresultsare
represented in Table 1.
However, all medium values obtained signiﬁcantly lie
above the cutoﬀ values used in this study (premenopausal
median: 27.1ng/mL, postmenopausal median: 37.1ng/mL).
The cutoﬀ values applied were recommended by the manu-
facturer of the immunoassay system [4].
When it comes to speciﬁcity and sensitivity we obtained
unsatisfactory results when using these cutoﬀ values. The
speciﬁcity obtained was 22%, and sensitivity reached 87%.
When using ROC analyses the perfect cutoﬀ-point
turned out to be 104ng/mL. The AUC value obtained was
0.66. ROC curve is represented in Figure 1.
The low speciﬁcity and sensitivity found stem from the
fact that all patients have conﬁrmed cancer. To receive better
values it would be necessary to look at the treatment the pa-
tient is receiving and look at the change of the P1NP concen-
tration during the course of treatment.
Furthermore we found that P1NP serum concentrations
represent the extent of bone involvement. Women with only
little bone involvement, that means with less than ﬁve sites
of skeletal metastases, showed lowest P1NP levels (median:
49.55ng/mL), whereas women with multiple osseous metas-
tases, that means more than ﬁve sites, showed quite high
values (median: 183.7ng/mL). Results are represented in
Table 2.
Thechangeinminimatobelowforthepatientwithmore
than 5 sites of bone metastases is most likely due to the fact
that the patient has been receiving treatment for a prolonged
period.
Furthermore we investigated the eﬀect of metastases
otherthanboneonP1NPserumlevels.AsaresultP1NPcon-
centrations were found to also be elevated in patients onlyPathology Research International 3
Table 2: Correlationbetween P1NPlevels andextent ofbonemeta-
stases.
Number of sites of skeletal metastases 1 >1 <55 >5
Median: P1NP ng/mL 37.1 50.62 52.79 183.7
Minimum: P1NP ng/mL 28.22 14.7 49.55 19.75
Maximum: P1NP ng/mL 45.89 163.5 156.0 981.6
Table 3: P1NP serum levels depending on diﬀerent sites of metas-
tases.






Median: P1NP l 52.79ng/mL 73.6ng/mL 162.75ng/mL
Minimum: P1NP 14.8ng/mL 16.3ng/mL 22.47ng/mL
Maximum: P1NP 561.1ng/mL 243.5ng/mL 981.6ng/mL
showing extraskeletal metastases. Highest serum P1NP levels
were obtained for the group of women with extensive metas-
tases in several sites including bone. Results are represented
in Table 3.
4. Discussion
At present, bone metastases are detected by imaging tech-
niques such as bone scintigraphy, X-ray photographs, and
computed tomography. These methods are quite expensive,
time-consuming and involve radiation exposure. Apart from
that, bone scintigraphy as a main tool for detecting bone
metastases shows high sensitivity but lacks speciﬁcity [5].
Therefore it would be interesting to ﬁnd favourable methods
for the early detection and assessment of skeletal metastases.
One approach is to identify bone markers either representing
bone resorption or bone formation as bone metastases inter-
fere with bone metabolism. Therefore several study groups
analysed the eﬀect of skeletal metastases on certain bone
markers. De la Piedra et al., for example, compared con-
centrations of several markers of bone turnover such as
P1NP, speciﬁc alkaline phosphatase, and procollagen type 1
aminoterminal telopeptide (NTX) in men suﬀering from
prostate carcinoma with and without bone involvement. All
investigated bone markers showed signiﬁcantly higher levels
in patients with bone metastases. For P1NP they found a
sensitivity as well as speciﬁcity of 100% [6]. A previous
study by Diaz-Martin et al. found similar values for P1NP
with regard to this question. In their study speciﬁcity was
87%; sensitivity reached 100% [7]. Jung et al. also obtained
signiﬁcantly higher values for P1NP in case of bone involve-
ment in comparison to the control group without bone
metastases [8].
In accordance to the studies represented higher P1NP
serum concentrations were found in women suﬀering from
breast cancer and bone metastases (median: 125.75ng/mL)
in comparison to the group without bone involvement
(73.61ng/mL). However, using the cutoﬀ values recommen-
ded by the producer we obtained unsatisfactory values for
sensitivity(87%)andspeciﬁcity(22%).Thisisduetothefact
that all patients had conﬁrmed cancer. Neither the stage of
therapy nor the stage of cancer was taken into account in this
study.
With respect to the question whether P1NP is useful in
assessingtheextentofboneinvolvementKoizumietal.found
that P1NP is a valid marker in representing the degree of
bonemetastases[9].Thereforethisstudysupportstheirﬁnd-
ings.InourstudywealsofoundthehighestP1NPconcentra-
tions in case of extensive bone involvement.
As a further result we found elevated P1NP serum levels
also in patients with extensive metastases other than bone.
These ﬁndings might support a study undertaken by Jensen
et al. showing that an aggressive cancer disease is correlated
to high P1NP levels. In their study, Jensen et al. were able to
prove that extensive P1NP levels are associated to an aggres-
sive progression of the disease with a shorter live expectancy
than the control group with lower P1NP levels [10].
5. Conclusions
TheresultsobtainedsuggestP1NPareavalidmarkerinasse-
ssing bone involvement in women with breast cancer. Due to
lack of sensitivity as well as speciﬁcity we cannot recommend
to replace conventional methods for detecting bone metas-
tases. However, in the case of unclear radiological results ele-
vated P1NP levels suggest metastases. Yet, P1NP can be seen
as a helpful tool for supervising and assessing the devel-
opment of bone metastases. This study did not take into
account the therapy prescribed. As further ﬁeld of investi-
gation, a study with regards to stage of cancer as well as treat-
ment would further show the usefulness of P1NP as indica-
tor.
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